XML 20 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaboration and Other Agreements, Boehringer Ingelheim International GmbH (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2010
USD ($)
Molecule
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Payment
Sep. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
Collaboration And Other Agreements [Line Items]            
Deferred revenue included in current liabilities   $ 7,163   $ 7,163   $ 14,248
Deferred revenue included in long-term liabilities   11,889   $ 11,889   16,472
Boehringer [Member]            
Collaboration And Other Agreements [Line Items]            
Agreement beginning date       October 2010    
Number Of Molecules To Be Developed And Commercialized Under Agreement | Molecule 10          
Non-refundable upfront payment $ 15,000          
Number of annual maintenance payments received | Payment       3    
Additional Potential Clinical Milestone Payments Under Agreement   41,000   $ 41,000    
Additional Potential Regulatory Milestone Payments Under Agreement   89,000   89,000    
Additional Potential Sales Milestone Payments Under Agreement   $ 83,000   $ 83,000    
Research obligation completion date       October 2015    
Clinical milestone payments under agreement          
Recognized revenue under agreement   $ 1,800 $ 4,900 $ 7,000 $ 11,000  
Deferred revenue   300   300   5,800
Deferred revenue included in current liabilities   300   300   5,800
Deferred revenue included in long-term liabilities   $ 0   $ 0   $ 0
Milestone payment